.png){kind=logo}
Isomorphic Labs secured a $2.1 billion Series B round to expand AI-driven drug discovery, clinical programs, and global hiring.
Alphabet is aggressively raising capital across global debt markets as AI infrastructure spending targets move toward the $180-190 billion annual range.
Investors are now funding companies with stronger operating models, commercial partnerships, and clear long-term monetization strategies.
The rules of startup funding have changed, and if you are still playing by the 2021 playbook, you are already behind. Investors across markets are no longer writing cheques on growth projections alone. As Aditya Shukla, partner at Bain & Company and head of its India PE practice, put it bluntly this week, ‘The diligence bar has reset.’
The data backs that up. Global VC (Venture Capital) and growth funding fell from around $25.7 billion in 2022 to $9.6 billion in 2023 before recovering to $13.7 billion in 2024 and about $16 billion in 2025. Capital is back, but the bar to access it is higher now.
Funding rounds above $250 million doubled in 2025. Meanwhile, the broader PE-VC market saw total deal value drop around 17% year-on-year, even as deal volumes rose nearly 10%. Investors are putting bigger bets on fewer, stronger businesses. This week's three deals sit squarely inside that shift. Each one is fundable for a different reason.
Isomorphic Labs is a London-based AI drug design company founded by Sir Demis Hassabis. The company closed a $2.1 billion Series B, one of the largest rounds in biotech this year.
Thrive Capital led the raise. Alphabet and GV returned as existing backers. MGX, Temasek, CapitalG, and the UK Sovereign AI Fund came in as new investors. The presence of sovereign wealth funds alongside venture and corporate capital in a single round, the growth prospects of AI-driven drug discovery in the long term.
Isomorphic builds an AI Drug Design Engine (IsoDDE). It is a platform that uses proprietary AI models to design medicines in multiple therapeutic areas and drug types. The aim is to compress years of expensive, high-failure-rate lab work into AI-guided predictions that are faster, more precise, and repeatable.
The $2.1 billion will fund three things. First and second are the continued development and scaling of IsoDDE, moving the company's internal drug programs toward clinical trials. Lastly, expanding its team across AI, engineering, drug design, and clinical disciplines at its sites in London, Cambridge (Massachusetts), and Lausanne.
Critically, Isomorphic already holds active partnerships with Novartis, Eli Lilly, and Johnson and Johnson, three of the world's largest pharmaceutical companies. These are commercial collaborations running inside live drug development pipelines. For investors who have been asking whether AI drug discovery actually works beyond benchmarks, Isomorphic is now well-funded enough to answer that with clinical results.
Alphabet's move this week was debt, and in a currency it has never used before. The Google parent company filed plans to sell Japanese yen-denominated bonds for the first time in its history.
According to Reuters, the offering is expected to reach a hundred billion yen, with final terms expected later this month. Mizuho Financial Group, Bank of America, and Morgan Stanley are running the transaction.
This funding round is part of a broader and aggressive capital raise running all year. Just last week, Alphabet pulled in nearly $17 billion in two separate deals, a €9 billion bond (around $10.3 billion) and a CA$8.5 billion transaction (roughly $6.1 billion). The company has raised tens of billions in three currencies in a matter of weeks if we include the yen deal.
The reason is scale. Industry estimates put combined Big Tech AI infrastructure spending at over $700 billion in 2026. It is up sharply from around $410 billion in 2025. Alphabet itself raised its annual capex forecast last month by $5 billion to a range of $180 billion to $190 billion, with further increases planned for 2027.
The market has rewarded the strategy. Alphabet's stock has gained roughly 160% over the past 12 months. Last week, it briefly overtook NVIDIA in market capitalisation during after-hours trading. The hike was partly driven by news that Anthropic had committed $200 billion in Google Cloud spending over five years for 5 gigawatts of computing capacity.
For debt investors, the yen deal opens a new currency access point to a company now among the most active corporate borrowers in international markets. For equity investors, the message is clear: Alphabet is building hard, and the market is pricing that in.
The smallest deal this week carries an interesting thesis. Webidoo, a Chicago and Milan-based AI company, closed a $25 million. The funding round was led by IXC3, the private investment arm of Italy's Azimut Group, with participation from existing backers 8a+ and TIM Ventures.
Webidoo builds AI platforms specifically for small and medium-sized businesses, a segment that has historically been the last to benefit from enterprise software. Its three products, Jooice, Groow, and Welpy, cover marketing automation, sales performance, and business operations. CEO Giovanni Farese is pointing the $25 million at two priorities; expanding the AI platforms and acquiring SaaS and marketing companies in the United States.
The acquisition-led US strategy is a faster route to scale than organic growth alone. It signals that Webidoo is not building slowly. The SMB automation market is large and still early. Enterprise-focused AI vendors rarely compete at this end of the market. For growth-stage investors looking for plays below the AI megadeal tier, this is the kind of round worth keeping an eye on.
The era of unlimited patient private capital rewarding growth at any cost is over. What is replacing it is discipline. Arpit Jain, joint MD at Arihant Capital Markets, described the shift plainly. The current environment, he said, is far more focused on business sustainability, cash flow visibility, and operating efficiency than on growth narratives alone.
Soumya Chauhan, principal at global investment group Prosus, said, " Foreign capital remains indispensable because of larger risk appetite and cheque sizes.” She added that domestic mutual funds, family offices, and crossover investors have meaningfully increased their participation.
That last point matters globally, not just in India. The three funding deals this week all reflect that. Isomorphic has clinical validation behind its raise. Alphabet has a balance sheet and infrastructure moat behind its debt. Webidoo has a concrete acquisition strategy for its $25 million ask. The money is now moving toward businesses that can show you why they deserve it.
Isomorphic Labs raised $2.1 billion in one of the biggest biotech funding rounds of 2026. The company uses AI to speed up drug discovery and reduce expensive trial-and-error lab work. Investors are paying attention because the company already has partnerships with large pharmaceutical firms like Novartis, Eli Lilly, and Johnson & Johnson. This gives the business stronger commercial credibility compared to early-stage AI biotech startups.
Alphabet is raising money through yen-denominated bonds to support its growing AI infrastructure spending plans. The company is investing heavily in data centers, cloud infrastructure, and computing power needed for artificial intelligence. By borrowing in different global currencies, Alphabet can access larger pools of capital while potentially lowering financing costs. The move also shows how serious Big Tech firms are about expanding AI capacity over the next few years.
Webidoo builds AI software tools for small and medium-sized businesses. Its platforms help companies automate marketing, sales, and business operations. The company raised $25 million to improve its AI products and expand through acquisitions in the United States. Investors view the small-business AI software market as an underdeveloped area with long-term growth potential, as many SMBs still lack advanced automation tools.
Investors are focusing more on profitability, cash flow, and business sustainability because funding conditions have changed sharply since 2021. Venture capital activity slowed significantly after 2022, forcing startups to more clearly demonstrate their business models. Today, companies with strong partnerships, operating efficiency, and realistic growth plans are more likely to attract funding than businesses that rely solely on future projections or aggressive expansion plans.
AI infrastructure, healthcare technology, automation software, and enterprise productivity tools are attracting strong investor interest in 2026. At the same time, investors are making fewer but larger bets on companies with proven execution. Funding rounds above $250 million have increased sharply, while many smaller startups are finding it harder to raise funds. Markets are rewarding businesses that can show clear commercial demand, operational scale, and long-term revenue visibility.
